Prognostic Significance of the Albumin Platelet Product for Mortality Risk in Pulmonary Embolism: A Retrospective Analysis Based on the MIMIC-IV Database.

ABSTRACT: BackgroundPulmonary embolism (PE) is a leading cause of cardiovascular mortality. The albumin platelet product (APP), a novel biomarker integrating nutritional and inflammatory status, is associated with adverse outcomes in various diseases. However, its prognostic value for mortality in patients with PE remains unclear.MethodsThis retrospective cohort study included 2355 patients with PE from the MIMIC-IV database. The primary exposure was APP, calculated as (albumin [g/dL]×platelet [K/µL]) / 100. The primary endpoints were all-cause mortality at 28 days, 90 days, and 365 days. The association between APP and mortality was assessed using restricted cubic splines (RCS), Kaplan-Meier survival curves, and multivariable Cox proportional hazards models. Subgroup analyses were performed to eval

SUBMITTER: Wu G 

PROVIDER: S-EPMC12673038 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature